Gorman Sean K, Slavik Richard S, Lam Stefanie
, BScPharm, ACPR, PharmD, is Clinical Coordinator-Critical Care, Pharmacy Department, Capital District Health Authority, and Associate Professor, College of Pharmacy, Dalhousie University, Halifax, Nova Scotia.
Can J Hosp Pharm. 2012 May;65(3):188-95. doi: 10.4212/cjhp.v65i3.1141.
Clinicians commonly rely on tertiary drug information references to guide drug dosages for patients who are receiving continuous renal replacement therapy (CRRT). It is unknown whether the dosage recommendations in these frequently used references reflect the most current evidence.
To determine the presence and accuracy of drug dosage recommendations for patients undergoing CRRT in 4 drug information references.
Medications commonly prescribed during CRRT were identified from an institutional medication inventory database, and evidence-based dosage recommendations for this setting were developed from the primary and secondary literature. The American Hospital Formulary System-Drug Information (AHFS-DI), Micromedex 2.0 (specifically the DRUGDEX and Martindale databases), and the 5th edition of Drug Prescribing in Renal Failure (DPRF5) were assessed for the presence of drug dosage recommendations in the CRRT setting. The dosage recommendations in these tertiary references were compared with the recommendations derived from the primary and secondary literature to determine concordance.
Evidence-based drug dosage recommendations were developed for 33 medications administered in patients undergoing CRRT. The AHFS-DI provided no dosage recommendations specific to CRRT, whereas the DPRF5 provided recommendations for 27 (82%) of the medications and the Micromedex 2.0 application for 20 (61%) (13 [39%] in the DRUGDEX database and 16 [48%] in the Martindale database, with 9 medications covered by both). The dosage recommendations were in concordance with evidence-based recommendations for 12 (92%) of the 13 medications in the DRUGDEX database, 26 (96%) of the 27 in the DPRF5, and all 16 (100%) of those in the Martindale database.
One prominent tertiary drug information resource provided no drug dosage recommendations for patients undergoing CRRT. However, 2 of the databases in an Internet-based medical information application and the latest edition of a renal specialty drug information resource provided recommendations for a majority of the medications investigated. Most dosage recommendations were similar to those derived from the primary and secondary literature. The most recent edition of the DPRF is the preferred source of information when prescribing dosage regimens for patients receiving CRRT.
临床医生通常依靠三级药物信息参考文献来指导接受持续肾脏替代治疗(CRRT)患者的药物剂量。尚不清楚这些常用参考文献中的剂量推荐是否反映了最新证据。
确定4种药物信息参考文献中针对接受CRRT患者的药物剂量推荐的存在情况及准确性。
从机构药物库存数据库中识别出CRRT期间常用的药物,并从一级和二级文献中制定该情况下基于证据的剂量推荐。评估《美国医院处方集系统 - 药物信息》(AHFS - DI)、Micromedex 2.0(特别是DRUGDEX和《马丁代尔药物大典》数据库)以及《肾衰竭药物处方》第5版(DPRF5)中CRRT情况下药物剂量推荐的存在情况。将这些三级参考文献中的剂量推荐与从一级和二级文献得出的推荐进行比较,以确定一致性。
为接受CRRT患者使用的33种药物制定了基于证据的药物剂量推荐。AHFS - DI未提供特定于CRRT的剂量推荐,而DPRF5为27种(82%)药物提供了推荐,Micromedex 2.0应用程序为20种(61%)药物提供了推荐(DRUGDEX数据库中有13种[39%],《马丁代尔药物大典》数据库中有16种[48%],9种药物在两个数据库中均有涵盖)。DRUGDEX数据库中13种药物中的12种(92%)、DPRF5中27种药物中的26种(96%)以及《马丁代尔药物大典》数据库中所有16种(100%)药物的剂量推荐与基于证据的推荐一致。
一种著名的三级药物信息资源未为接受CRRT的患者提供药物剂量推荐。然而,基于互联网的医学信息应用程序中的两个数据库以及肾脏专科药物信息资源的最新版本为大多数研究的药物提供了推荐。大多数剂量推荐与从一级和二级文献得出的推荐相似。在为接受CRRT的患者制定剂量方案时,DPRF的最新版本是首选的信息来源。